Opinions expressed in articles and other materials are those of the authors; they do not necessarily reflect IMF policy. SOURCES: Coursera. 2023. “Artificial Intelligence (AI) Terms: A to Z Glossary.” ...

It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...

Lexicon Pharmaceuticals shares were 21% lower, at $1.14, after the company priced its underwritten public offering of 32 million shares at $1.30 a share. All of the shares are being offered by Lexicon ...

Lexicon Pharmaceuticals (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, visits the Nasdaq MarketSite in Times Square to commemorate ...

Lexicon Inc., a Little Rock-based construction management and steel fabrication company, said Thursday it has become a private, employee-owned company. Lexicon said the decision comes after a ...

Dezeen Showroom: Italian brand Fiandre aimed to create a "vocabulary of surfaces" with the Lexicon tile collection, featuring eight high-tech stone- and marble-inspired designs. Both atmospheric, ...

A town's major shopping centre has reportedly been bought by an investment firm for about £150m. US-based Realty Income bought The Lexicon in Bracknell from previous owners Schroder Capital UK Real ...

Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...

THE WOODLANDS, Texas — A Houston-area pharmaceutical company has struck a billion-dollar deal with the seller of Ozempic for a potential drug also aiming to combat obesity. Lexicon Pharmaceuticals Inc ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and shifted ...